Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis By 2026 Lysosomal acid lipase (LAL) deficiency is a rare inherited condition in which the body is not able to produce enough lysosomal acid lipase (LAL) enzyme, which is an important enzyme for breakdown of fatty materials namely cholesteryl esters and triglycerides. This results in building up of a large amount of fatty material in body organs, which include spleen, liver, and gut. The deficiency of LAL causes two autosomal recessive disorders, Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD). LAL deficiency is caused due to the genetic mutation in LIPA gene, which results in decrease or loss of Lysosomal Acid Lipase (LAL) enzyme. Ask Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/904 FDA approval of innovative drugs is expected to fuel the growth of Lysosomal Acid Lipase (LAL) Deficiency Treatment Market The approval of innovative drugs by Food and Drug Administration (FDA) is expected to augment the growth of market. In 2015 the U.S. Food and Drug Administration (FDA) approved Alexion Pharmaceutical’s Kanuma (sebelipase alfa), an innovative enzyme replacement therapy (ERT). Kanuma is first approved therapy that treats the underlying cause of the disease. It is the only therapy for the treatment of LAL deficiency. As it is the only available therapy in market, kanuma is expected to have a significant market growth in the near future. According to the National Institute for Health and Care Excellence (NICE) 2016, around 50% of patients suffering from lysosomal acid lipase (LAL) deficiency have chances of liver complications, which includes cirrhosis or fibrosis and liver transplant. The increasing incidences of liver complications due to LAL deficiency is expected to increase demand for liver transplant, in turn fueling the growth of LAL deficiency treatment market over the forecast period. High cost and lack of awareness about diagnosis and treatment among people is the major restraint for the growth of Lysosomal Acid Lipase (LAL) Deficiency treatment market. North America is expected to dominate market due to rapid novel innovations Global market for the Lysosomal Acid Lipase (LAL) deficiency treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the lysosomal acid lipase (LAL) deficiency treatment market attributed to rapid novel innovations, drug development, and research. In 2015, FDA approved genetically modified organisms (GMO) chickens, for the production of a recombinant human lysosomal acid lipase (LAL) protein in their eggs for the treatment of lysosomal acid lipase (LAL) deficiency among Americans. Europe is expected to be the second largest region for LAL deficiency treatment market. The Europe commission in 2015 granted marketing permission of Kanuma, for the treatment of LAL deficiency for patients of all ages, which is expected to fuel the growth of kanuma in region. Report includes chapters which deeply display the following deliverable about industry : • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Research Objective and Assumption • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market, By Regions • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Rapid approval of therapy by FDA in various region, be an opportunities for companies Ltd. In 2015, FDA approved Kanuma, an innovative enzyme replacement therapy (ERT) in the U.S., Europe Union, and Japan, which is providing an opportunity to manufacturers for exploring their business in the untapped market. Major players operating in global Lysosomal Acid Lipase (LAL) Deficiency treatment market include Alexion Pharmaceutical Inc., Merck & Co., Inc., Pfizer, Inc., and AstraZeneca plc. and Teva Pharmaceutical Industries. Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Taxonomy: The global Lysosomal Acid Lipase (LAL) deficiency treatment market is segmented on the basis of disease type, treatment type, and end user. On The Basis Of Disease Type: • Wolman Disease • Cholesteryl Ester Storage Disease (CESD) On The Basis Of Treatment Type: • Liver Transplant • Hematopoietic Stem Cell Transplant Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/lysosomal-acid-lipase-deficiency-treatment-market-904 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Lysosomal acid lipase (LAL) deficiency is a rare inherited condition in which the body is not able to produce enough lysosomal acid lipase (LAL) enzyme, which is an important enzyme for breakdown of fatty materials namely cholesteryl esters and triglycerides.
© Copyright 2024 Paperzz
